FDA official tells firms "be conscious of vulnerabilities"
This article was originally published in Scrip
Executive Summary
A lesson for companies in the wake of the heparin adulteration which occurred last year is that vulnerabilities can and should be monitored, Deborah Autor, director of compliance in the US FDA's drug centre, told attendees at the recent DCAT meeting in New York.